Drugs Containing Excipient (Inactive Ingredient) CARBOXYMETHYLCELLULOSE SODIUM

« Back to Dashboard

Branded drugs containing CARBOXYMETHYLCELLULOSE SODIUM excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	KENALOG-40	triamcinolone acetonide	0003-0293	CARBOXYMETHYLCELLULOSE SODIUM
ER Squibb & Sons LLC	KENALOG-10	triamcinolone acetonide	0003-0494	CARBOXYMETHYLCELLULOSE SODIUM
Allergan Inc	ACUVAIL	ketorolac tromethamine	0023-3507	CARBOXYMETHYLCELLULOSE SODIUM
Allergan Inc	ALPHAGAN P	brimonidine tartrate	0023-9321	CARBOXYMETHYLCELLULOSE SODIUM

Generic drugs containing CARBOXYMETHYLCELLULOSE SODIUM excipient

Company	Ingredient	NDC	Excipient
ER Squibb & Sons LLC	triamcinolone acetonide	0003-0293	CARBOXYMETHYLCELLULOSE SODIUM
ER Squibb & Sons LLC	triamcinolone acetonide	0003-0494	CARBOXYMETHYLCELLULOSE SODIUM
Allergan Inc	ketorolac tromethamine	0023-3507	CARBOXYMETHYLCELLULOSE SODIUM
Allergan Inc	brimonidine tartrate	0023-9321	CARBOXYMETHYLCELLULOSE SODIUM

Carboxymethylcellulose Sodium Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 19, 2026

Carboxymethylcellulose sodium, commonly called sodium carboxymethylcellulose, cellulose gum, or CMC sodium, is a mature, regulated pharmaceutical excipient used as a binder, viscosity modifier, suspending agent, stabilizer, disintegrant, and ophthalmic lubricant. The market is fragmented across pharmaceutical, food, personal-care, industrial, and oilfield applications. Pharmaceutical-grade CMC is a smaller but higher-value segment with better pricing, stronger qualification barriers, and more stable demand than industrial-grade material.

The financial outlook is positive but moderate. Volume growth is likely to remain in the low- to mid-single digits, while revenue growth will depend on pharmaceutical formulation activity, ophthalmic demand, specialty oral solid-dose products, input-cost recovery, and the premium paid for compendial, low-endotoxin, and validated grades. The molecule itself has little meaningful patent protection. Competitive advantage rests on manufacturing consistency, regulatory documentation, customer qualification, supply reliability, and formulation performance.

What is carboxymethylcellulose sodium used for in pharmaceuticals?

Carboxymethylcellulose sodium is a water-soluble cellulose derivative produced by reacting cellulose with sodium hydroxide and monochloroacetic acid or sodium monochloroacetate. Its performance depends on degree of substitution, molecular weight, viscosity, particle size, purity, and moisture content.

Pharmaceutical function	Typical application
Binder	Tablets and granules
Viscosity modifier	Oral liquids, ophthalmic products, topical formulations
Suspending agent	Suspensions and emulsions
Stabilizer	Multiphase liquid formulations
Disintegrant	Selected immediate-release solid dosage forms
Lubricating polymer	Artificial tears and ocular products
Mucoadhesive or rheology modifier	Topical and mucosal formulations

The excipient is listed in major pharmacopeial systems, including the United States Pharmacopeia-National Formulary, European Pharmacopoeia, and Japanese Pharmacopoeia. The FDA Inactive Ingredient Database includes carboxymethylcellulose sodium across multiple dosage forms and routes, supporting its use as an established excipient rather than an experimental formulation material (U.S. Food and Drug Administration, n.d.-a).

Pharmaceutical applications typically require tighter controls than food or industrial grades. Customers may specify viscosity ranges, degree of substitution, microbial limits, elemental impurities, residual solvents, endotoxin limits, particle-size distribution, and batch-to-batch rheology.

How large is the pharmaceutical carboxymethylcellulose sodium market?

Public market reports generally combine pharmaceutical CMC with food, personal-care, industrial, construction, oilfield, and other cellulose-ether uses. They do not provide a consistent, audited figure for pharmaceutical-grade CMC sodium alone.

The addressable pharmaceutical segment is best understood through market structure rather than a single reliable market number:

1. Industrial and food applications account for most global CMC volume.
2. Pharmaceutical grade represents a smaller share but commands a material price premium.
3. The highest-value products are highly purified, low-bioburden, low-endotoxin, high-viscosity, and application-specific grades.
4. Contract development and manufacturing activity creates demand for multiple grades rather than one standardized product.
5. Customers often qualify a supplier for a specific grade and manufacturing site, which reduces short-term switching.

A reasonable commercial model is that pharmaceutical CMC grows faster than mature industrial CMC because it benefits from expanding generic medicines, ophthalmic products, oral liquids, and excipient substitution. The market remains too fragmented for a dependable standalone global revenue estimate from public filings.

What is driving demand for pharmaceutical-grade CMC sodium?

Generic and oral solid-dose manufacturing

CMC sodium remains relevant in generic tablets, granules, and suspensions because it is inexpensive, widely documented, and compatible with common manufacturing processes. Generic manufacturers favor excipients with established regulatory histories and broad compendial acceptance.

Demand is strongest where CMC sodium can replace or complement more expensive polymers, including selected grades of hypromellose, povidone, crospovidone, and microcrystalline cellulose. Substitution is formulation-specific. CMC sodium cannot be treated as a universal replacement because its hydration profile, ionic character, viscosity, and compression behavior differ from those of neutral cellulose ethers.

Ophthalmic and artificial-tear products

Ophthalmic products are a higher-value application. CMC sodium is used as a lubricant in artificial tears and other ocular formulations. Demand benefits from aging populations, increased diagnosis of dry-eye disease, screen-related eye discomfort, and expansion of preservative-free products.

Ophthalmic-grade supply has greater qualification requirements than ordinary tablet-grade material. Customers may require low endotoxin, low particulate burden, tight viscosity control, sterility compatibility, and validated microbial-control processes.

Oral liquids and suspensions

CMC sodium provides viscosity and suspension stability in oral liquids. It is particularly useful where the active ingredient has poor aqueous solubility or where sedimentation control is needed. Pediatric and geriatric formulations can support demand because these products often use liquid dosage forms to improve administration.

Biologics and biosimilars

CMC sodium is not a biologic active ingredient and does not face biosimilar substitution risk. Its role in biologics is limited compared with excipients such as polysorbates, sugars, amino acids, and surfactants. It may appear in ancillary, topical, delivery, or combination formulations, but biologics are not the primary growth engine for pharmaceutical CMC sodium.

How does the pharmaceutical CMC sodium supply chain work?

CMC sodium production begins with purified cellulose, generally sourced from wood pulp or cotton linters. The manufacturing process involves alkalization, etherification, washing, neutralization, drying, milling, blending, and packaging.

The main cost drivers are:

• Cellulose pulp and cotton-linter prices
• Caustic soda and etherifying-agent costs
• Energy and water consumption
• Waste treatment and solvent recovery
• Quality-control testing
• Cleanroom or controlled-environment packaging
• Regulatory maintenance and customer audits
• Freight and inventory costs

The chemical reaction is established and widely practiced. The barrier is not basic process know-how. It is consistent production at the required purity, viscosity, microbiological quality, and documentation standard.

Pharmaceutical customers increasingly seek dual sourcing, but qualification of a second supplier can take months or years. A change in raw-material source, manufacturing site, process parameters, or grade specification can trigger regulatory filings or customer requalification.

Which companies supply pharmaceutical-grade carboxymethylcellulose sodium?

The competitive market includes diversified specialty-chemical companies, cellulose manufacturers, and excipient specialists.

Company or supplier group	Relevant market position
Ashland	Supplies cellulose derivatives and pharmaceutical excipients under its pharmaceutical and specialty-ingredients portfolio
JRS PHARMA	Markets pharmaceutical excipients, including cellulose-based products and formulation-specific grades
Nippon Paper Industries	Produces cellulose derivatives and pharmaceutical-related cellulose products
Lamberti	Supplies cellulose-based rheology modifiers and specialty ingredients
DKS Co. Ltd.	Produces cellulose derivatives and related specialty chemicals
Regional Chinese and Indian manufacturers	Supply pharmaceutical, food, and industrial CMC grades, often competing on price and capacity
Specialty distributors	Provide regional inventory, technical support, and regulatory documentation

The supplier landscape is broader than the pharmaceutical segment. Many producers sell CMC into food, detergents, paper, ceramics, textiles, drilling fluids, construction chemicals, and personal care. Pharmaceutical customers generally prefer suppliers with dedicated pharmaceutical documentation, recognized quality systems, change-control procedures, and a history of regulatory support.

How strong is the patent estate for carboxymethylcellulose sodium?

The core composition of matter is not meaningfully patent-protected. Carboxymethylcellulose sodium is a mature cellulose derivative with a long commercial history.

Protection may still exist around:

• Manufacturing processes
• Narrow degree-of-substitution ranges
• Specific viscosity profiles
• Low-endotoxin or low-bioburden production methods
• Particle engineering
• Co-processed excipient systems
• Modified-release formulations
• Ophthalmic compositions
• Drug-excipient combinations
• Proprietary grades for specific dosage forms

These rights generally protect a product configuration, manufacturing process, or formulation rather than the basic molecule. Patent risk for a pharmaceutical company using off-the-shelf CMC sodium is therefore usually low. The main legal risk concerns contractual confidentiality, trade secrets, specifications, and process know-how.

What is the regulatory status of carboxymethylcellulose sodium?

CMC sodium is an established inactive ingredient, not an active pharmaceutical ingredient. Its regulatory status is generally favorable when the proposed grade, route, concentration, and function are supported by precedent.

FDA status

The FDA Inactive Ingredient Database identifies prior use by dosage form and route. A formulation sponsor must still demonstrate that its selected grade is suitable for the proposed product and concentration. Listing in the database does not automatically approve every supplier, specification, route, or dosage level.

The FDA’s excipient framework places emphasis on identity, purity, manufacturing controls, impurities, residual materials, microbial quality, and suitability for the finished dosage form (U.S. Food and Drug Administration, n.d.-a; U.S. Food and Drug Administration, n.d.-b).

European status

European pharmaceutical use is supported by the European Pharmacopoeia monograph and the European Medicines Agency’s excipient guidance. Sponsors must provide adequate quality information in the relevant regulatory submission, including specifications and control strategy (European Directorate for the Quality of Medicines & HealthCare, n.d.; European Medicines Agency, 2016).

Orange Book status

CMC sodium does not have an Orange Book listing because the Orange Book identifies approved drug products and their patent and exclusivity information. It does not list ordinary excipients as independently protected drug products.

When does carboxymethylcellulose sodium lose exclusivity?

CMC sodium has no meaningful compound-level exclusivity period comparable to a small-molecule active pharmaceutical ingredient. It is already a mature, widely available excipient.

Exclusivity can arise at the product or supplier level through:

• Proprietary grades
• Customer-specific specifications
• Trade secrets
• Manufacturing know-how
• Confidential quality agreements
• Regulatory qualification
• Temporary capacity constraints
• Contractual supply arrangements

These commercial protections are usually more important than patents. A customer may remain with an incumbent supplier because switching creates analytical, stability, manufacturing, and regulatory costs even when alternative suppliers legally can sell the same type of excipient.

Are there Paragraph IV challenges involving CMC sodium?

Paragraph IV litigation generally applies to patents listed in the FDA Orange Book for an approved drug product. CMC sodium, as an excipient, is not normally the subject of a standalone Paragraph IV challenge.

A generic drug containing CMC sodium may file a Paragraph IV certification against patents covering the finished drug, formulation, method of use, or manufacturing process. In that situation, the legal dispute concerns the drug product, not the underlying availability of CMC sodium as a commodity excipient.

What litigation and settlement risks affect the market?

Public litigation risk for the base excipient is limited. The more relevant disputes involve:

• Alleged infringement of formulation patents
• Trade-secret claims involving cellulose-derivative manufacturing
• Supply interruptions and quality failures
• Product specifications and out-of-specification batches
• Regulatory disclosure obligations
• Contract termination and change-control disputes

Settlement agreements are more likely to arise in drug-product patent litigation than in the CMC sodium supply market. Publicly disclosed licensing deals tied specifically to pharmaceutical-grade CMC sodium are limited. Licensing activity is more common for proprietary drug delivery systems, co-processed excipients, or finished formulations that use CMC sodium as one component.

What is the financial trajectory for pharmaceutical CMC sodium?

The financial trajectory is steady rather than transformational.

Financial factor	Expected effect
Pharmaceutical volume growth	Positive, low to mid single digits
Ophthalmic demand	Positive, above-average value contribution
Generic-drug growth	Positive but price-sensitive
Raw-material inflation	Pressures margins unless recovered through pricing
Energy and freight costs	Volatile margin impact
Premium pharmaceutical grades	Supports gross margin
Chinese capacity expansion	Increases price competition
Supplier qualification	Supports retention and switching costs
Regulatory failures	Can create disproportionate revenue loss
Industrial diversification	Reduces dependence on pharmaceuticals

Pharmaceutical-grade CMC has a better margin profile than commodity industrial CMC because customers pay for documentation, consistency, compliance, and supply assurance. The premium is constrained by the availability of lower-cost Asian suppliers and by the fact that CMC sodium is not a high-cost component in most drug products.

A supplier with strong pharmaceutical exposure can improve margins by selling application-specific grades, offering technical services, maintaining regional inventory, and supporting regulatory submissions. A supplier competing only on standard viscosity grades faces greater commoditization.

Public-company financial reporting rarely isolates pharmaceutical CMC revenue. Ashland reports broader specialty-ingredients and pharmaceutical activities rather than a standalone CMC sodium line item. Nippon Paper reports larger pulp, paper, and functional-material businesses rather than separate pharmaceutical CMC revenue. Financial analysis therefore requires segment-level proxies instead of a pure product revenue series (Ashland Global Holdings Inc., 2023; Nippon Paper Industries Co., Ltd., 2024).

What generic launch risks exist for products using CMC sodium?

The presence of CMC sodium does not normally block generic entry. Generic launch risk instead depends on the finished product’s patent and regulatory profile.

Key scenarios include:

Launch scenario	CMC sodium impact
Immediate-release tablet	Low legal risk; supplier qualification remains relevant
Oral suspension	Moderate technical risk if viscosity and sedimentation are critical
Artificial tears	Higher quality and sterility expectations
Modified-release dosage form	Potential formulation-patent risk
Pediatric liquid	Higher palatability, stability, and viscosity sensitivity
Complex topical product	Greater process and equivalence risk
Biosimilar	Usually limited relevance

A generic sponsor may use a different CMC sodium supplier if the alternative grade produces equivalent quality and performance. The switch may require comparative testing, stability work, process adjustments, and regulatory documentation.

How does CMC sodium compare with other pharmaceutical cellulose excipients?

Excipient	Main advantage	Main limitation
CMC sodium	Water solubility, viscosity control, broad functionality	Ionic behavior and variable hydration
Hypromellose	Strong film formation and controlled-release utility	Often higher cost and more formulation-specific
Microcrystalline cellulose	Excellent tablet filler and dry-binder performance	Insoluble in water
Hydroxypropyl cellulose	Binder and film-forming performance	Different thermal and hydration behavior
Crospovidone	Fast disintegration	Limited viscosity function
Povidone	Binding and solubilization	Hygroscopicity and peroxide concerns in some systems

CMC sodium competes most directly where water solubility, suspension stability, and rheology are important. It is less interchangeable with microcrystalline cellulose in dry tableting and less directly comparable with crospovidone in superdisintegration.

What geographic trends will shape the market?

Asia remains central to CMC production capacity and cost competition. China and India have expanding pharmaceutical manufacturing bases and a broad supplier network. Europe and North America retain advantages in regulated-market documentation, customer service, specialty grades, and proximity to major drug manufacturers.

Regional buyers are placing greater emphasis on:

• Dual sourcing
• Local or regional inventory
• Manufacturing-site transparency
• Excipient risk assessments
• Supply continuity plans
• Change-notification periods
• Audit access
• Nitrosamine and elemental-impurity controls where relevant

The result is a two-tier market. Standard pharmaceutical grades face price pressure, while validated specialty grades benefit from customer retention and technical barriers.

Key Takeaways

• Pharmaceutical-grade CMC sodium is a mature excipient market with moderate growth and limited compound-level patent risk.
• The most attractive applications are ophthalmic lubricants, oral liquids, suspensions, and specialized solid-dose formulations.
• Regulatory documentation, microbial control, viscosity consistency, and supply reliability create the principal commercial barriers.
• FDA Orange Book exclusivity and Paragraph IV litigation do not normally apply to CMC sodium itself.
• Formulation patents may still affect finished drugs that use CMC sodium.
• Pharmaceutical-grade products earn a premium over food and industrial grades, but Asian capacity limits pricing power.
• Public companies do not generally disclose standalone CMC sodium revenue, so financial analysis relies on broader specialty-ingredient and cellulose-derivative segments.
• The strongest suppliers will combine compendial quality, application development, dual-region manufacturing, and regulatory support.

FAQs

Is carboxymethylcellulose sodium the same as cellulose gum?

Yes. Carboxymethylcellulose sodium, sodium carboxymethylcellulose, and cellulose gum are commonly used names for the same cellulose derivative, although commercial grades differ in purity, viscosity, particle size, and regulatory specification.

Is pharmaceutical-grade CMC sodium interchangeable between suppliers?

Not automatically. Two grades may meet the same pharmacopeial monograph yet behave differently in hydration rate, viscosity, particle size, impurity profile, or tablet processing. Formulation and regulatory assessment is required before substitution.

Does CMC sodium affect drug bioequivalence?

It can. Changes in viscosity, disintegration, suspension stability, dissolution, or drug release may affect product performance. The impact depends on the dosage form and the excipient’s functional role.

Is CMC sodium used in injectable medicines?

Use in parenteral products is more constrained than in oral, topical, or ophthalmic products. The proposed route requires specific safety, purity, particulate, endotoxin, and regulatory support.

Can a pharmaceutical company manufacture CMC sodium without a license?

The basic molecule is not generally protected by an active composition-of-matter patent. A manufacturer may still encounter process patents, trade secrets, contractual restrictions, regulatory qualification requirements, and customer-specific specifications.

References

Ashland Global Holdings Inc. (2023). 2023 annual report. Ashland Global Holdings Inc.

European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia: Sodium carboxymethylcellulose monograph. Council of Europe.

European Medicines Agency. (2016). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. European Medicines Agency.

Nippon Paper Industries Co., Ltd. (2024). Integrated report 2024. Nippon Paper Industries Co., Ltd.

U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. U.S. Department of Health and Human Services.

U.S. Food and Drug Administration. (n.d.-b). Drug products, including biological products, that contain inactive ingredients. U.S. Department of Health and Human Services.

United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Carboxymethylcellulose sodium. United States Pharmacopeial Convention.